Abstract 4158
Background
Tumor-associated macrophages (TAMs) constitute over 50% of the number of cells in breast malignancies. In mouse models, most TAMs in the breast cancer microenvironment behave as the M2-like phenotype, with protumor characteristics, but the roles of TAMs in human breast cancer are poorly understand. Specific TAMs related molecular mechanisms among different intrinsic molecular subtypes remain unclear. Here, we focused on studying protumor TAM markers among human breast cancer tissues: CD163, CD204, CD206 which commonly used in mouse models. We identify and explore roles of TAMs novel marker: CD204 in intrinsic molecular subtypes of breast cancer.
Methods
Expression of CD204, CD163, CD206 and clinical outcome of CD204 were analyzed using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. Potential Kyoto Encyclopedia of Genes and Genomes (KEGG) and HALLMARK pathways regulated by CD204 were studied using Gene Set Enrichment Analysis (GSEA). We used CIBERSOT to estimate the immune contextures regulated by CD204 among different subtypes and the correlations of CD204 and immune suppressive molecules were also analyzed.
Results
Compared to CD163, CD206, only CD204 was found upregulated in breast cancer compared to the normal tissue, associated with poor OS, RFS, and DMFS. The expression of CD204 was different between 4 subtypes. CD204 was involved in immune system-related pathways including innate and adaptive immunity among all subtypes. Numerous special pathways were also found influenced by CD204: tumor metabolism-related pathways in luminal A, Hippo and TGF-β signaling pathways in luminal B, cell cycle process in HER-2 amplified, and RIG-I-like receptor signaling pathway in basal-like subtype. Strong correlations between CD204 and immune cells especially for protumor populations were displayed, and most immunosuppressive molecules: HIF1A, FAP, IL10, PDCD1/CD274, CTLA4, HAVCR2, positive correlated with CD204 expression in all subtypes.
Conclusions
CD204 could become an applicable marker of TAMs in human breast cancer. These findings contribute to better understanding and managing of TAMs in different subtypes of breast cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jinhai Tang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2108 - Biomarker analyses of ramucirumab in patients with platinum refractory urothelial cancer from RANGE, a global, randomized, double-blind, phase 3 study.
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3090 - Comparison of Immuno-Oncology (IO) Biomarkers in Adenocarcinoma (ACB), Urothelial Carcinoma (UCB) and Squamous Cell Carcinoma (SCCB) of the Bladder, with interim results from PURE01
Presenter: Daniele Raggi
Session: Poster Display session 3
Resources:
Abstract
5211 - Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
Presenter: Albert Font
Session: Poster Display session 3
Resources:
Abstract
3206 - Hyperphosphatemia due to Erdafitinib (a Pan-FGFR Inhibitor) and Anti-tumor Activity Among Patients (Pts) with Advanced Urothelial Carcinoma (UC)
Presenter: Scott Tagawa
Session: Poster Display session 3
Resources:
Abstract
3110 - Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting
Presenter: Florian Roghmann
Session: Poster Display session 3
Resources:
Abstract
3564 - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)
Presenter: Jean-Michel Lavoie
Session: Poster Display session 3
Resources:
Abstract
2760 - Comparative analysis of tumor mutational burden (TMB) prediction methods and its association with determinants of the tumor immune microenvironment of urothelial bladder cancer (UBC)
Presenter: Markus Eckstein
Session: Poster Display session 3
Resources:
Abstract
2513 - The Immunoscore in patients with urothelial carcinoma treated with neoadjuvant chemotherapy: clinical significance for pathological response and survival
Presenter: Elise Nassif
Session: Poster Display session 3
Resources:
Abstract
2835 - Genomic analysis of urothelial cancer and associations with treatment choice and outcome
Presenter: David Sarid
Session: Poster Display session 3
Resources:
Abstract
5763 - cfDNA is an acceptable but insufficient means of characterizing FGFR3 mutation in patients with metastatic urothelial cancer (mUC)
Presenter: Sumanta Pal
Session: Poster Display session 3
Resources:
Abstract